- Tandem Diabetes Care has revamped its diabetes management platform for insulin pump users and healthcare providers.
- The platform, Tandem Source, combines the features of the company’s legacy t:connect offerings with new data reports that consolidate the information healthcare providers need to make recommendations.
- Tandem Source sits alongside two continuous glucose monitor (CGM) sensor integrations on the launch schedule, with the company recently connecting to Dexcom G7 and working to integrate with Abbott’s Freestyle Libre.
Tandem Source serves two sets of users, CEO John Sheridan explained at an investor event held by Jefferies last month. The product is a “data management platform that's actually inside the healthcare provider's offices,” Sheridan said, and patients who use Tandem pumps can get access to it on their computers.
“We've had a system on the market for 10 years now, and we've completely revamped it,” the CEO said. “It has data that the physicians themselves can determine exactly what they see and what they want to see, use this type of technology so they can choose different graphs ... that help them better manage the patient’s diabetes situation.”
Patients can use the platform to access data, reorder supplies and update their pump software. Users of the old t:connect offerings had to download a software program to upload pump data. Tandem Source uses a web-based pump uploader that Tandem said “offers faster data transfers to the cloud.” Automatic data transfers between pumps and the t:connect mobile app are possible, too.
Tandem will automatically transfer the data held by current t:connect Portal or t:connect HCP users to the new platform. The company has completed the rollout of Tandem Source in the U.S., which was “almost” finished when Sheridan spoke one month ago, and is planning to make it available internationally next year.
Sheridan identified Tandem Source as part of a sequence of launches featuring the new Mobi pump and integrations with Dexcom and Abbott CGMs at the event last month. The CEO predicted 2024 is “going to be a transformational year for us as a result of these new products” at another investor event late last month. Shares in Tandem have fallen 40% this year to $27.15 when the market closed on Thursday.